secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003211
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise
--------------------------------------------------------------------------------

- Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.
- Offering priced at-the-market under Nasdaq rules: $2.85 per unit (share or pre-funded warrant plus Common Stock warrant).
- Warrants exercisable at $3.28 per share, subject to stockholder approval, expire 5.5 years after approval.
- Company terminated Northland at-the-market agreement; only $89,792 raised under that facility.
- Proceeds to advance Halneuron Phase 2b final data readout and pursue strategic opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/0001104659-26-003211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926003211/dwtx-20260109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer